Skip to content
Review Open access

Harnessing the ubiquitin-proteasome system: advances and challenges of PROTACs in breast cancer

Oct 2026 · Molecular Biology Reports · Vol 53 · 0 citations · 81 references
Medicine

TL;DR

Overall, PROTACs can become a novel therapeutic approach in the treatment of breast cancer, and a knowledge gap exists that limits the understanding of E3 ligases, constraining their tissue specificity and metabolism.

Abstract

Breast cancer is one of the most significant health issues in the world, and resistance to treatment and a lack of targets that can be addressed with drugs limit the effectiveness of the existing treatment options. The development of proteolysis-targeting chimeras (PROTACs) has shifted the concept of occupancy-based inhibition toward event-based targeted protein degradation. Avoiding ubiquitin-proteasome hijacking, PROTACs target disease-relevant proteins to E3 ligases, allowing them to be catalytically degraded, thereby eliminating formerly undruggable or resistant targets. Their modular design, consisting of a warhead, linker, and E3 ligase ligand, eases rational design, but there are still difficulties, including hook effects, poor pharmacokinetics, and off-target toxicity. PROTACs have been known to undergo evolution, such as PHOTACs, CLIPTACs, and RIBOTACs, which have expanded therapeutic approaches. Clinical trial molecules such as ARV-471 have demonstrated an effective role in the degradation of ER+, showcasing their broader significance in HER2 by degrading BRD4, CDK, and PD-L1. However, a knowledge gap exists that limits our understanding of E3 ligases, constraining their tissue specificity and metabolism. Prospective directions focus on computational strategies to design E3 ligase-based PROTAC prodrugs, nanostructured PROTACs, and test them in vivo using organoids and xenograft models. Overall, PROTACs can become a novel therapeutic approach in the treatment of breast cancer.

Read PDF

Similar papers

Review Nov 2026

Beyond Inhibition: Emerging Approaches in Ubiquitin–Proteasome‐Mediated Protein Degradation for Precision Targeting

Targeted protein degradation (TPD) represents an emerging paradigm in drug discovery, capable of overcoming the limitations of traditional therapeutic strategies based on protein inhibition. Exploiting the ubiquitin–proteasome system (UPS), TPD allows the selective elimination of pathologically relevant proteins. The m...

M. Aliberti, M. Chini, Giuseppe Bifulco et al. · 0 citations
Review Open access Oct 2026

Targeted protein degradation in cancer: strategies for undruggable targets and progress towards clinical translation

Targeted protein degradation (TPD) has significantly influenced cancer therapy by enabling the targeting of traditionally undruggable oncogenic drivers such as transcription factors, chromatin remodelers, and mediators of protein-protein interactions, overcoming limitations of conventional inhibitors. This approach har...

Jin-Xin Tang, Ze Cheng, Tian-Chen Xie et al. · 0 citations
Review Open access Nov 2026

PROTAC-induced protein degradation in lung cancer.

ABSTRACT Lung cancer, the leading cause of cancer-related mortality worldwide, remains a formidable therapeutic challenge due to profound tumor heterogeneity and the emergence of drug resistance. Conventional small-molecule inhibitors that rely on an occupancy-driven mechanism are frequently undermined by acquired muta...

Ji-Rui Wen, Yu-Hao Zou, Tang Feng et al. · 0 citations
Review Open access Nov 2026

Rewriting protein fate: emerging strategies for targeted protein degradation and associated challenges

Abstract Classical small-molecule drugs have traditionally relied on an occupancy-driven paradigm that requires tight and sustained binding to a well-defined pocket on the target protein. Targeted protein degradation (TPD) approaches have emerged to overcome the limitations of traditional pharmacology to promote the se...

Andrea Bertran-Mostazo, Rosa Barrio · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.